If you are designing a study, the takeaway is that the strongest signal is in skin and connective-tissue models, the supporting literature concentrates around the Pickart groups body of work, and effects outside those model systems should be treated as more provisional
Effective January 1, 2026, Medi-Cal Rx is excluding coverage for GLP-1 medications prescribed for weight loss: [12] Wegovy, Zepbound, Saxenda: Completely removed from the Contract Drugs List for weight loss Ozempic, Mounjaro, Rybelsus: Restricted to Type 2 diabetes onlyweight loss claims will auto-deny Existing prior authorizations end December 31, 2025 Exceptions: Members under age 21 may still qualify via EPSDT Non-weight-loss indications (Zepbound for OSA, Wegovy for cardiovascular) may still get PA approval This does NOT affect Kaiser commercial or employer-sponsored plansonly Medi-Cal members
There have been substantial evidences that metformin has a regulatory effect on the gut microbiota (Zhang et al., 2015
Food and Drug Administration Safety, Sourcing, and How to Read a Collagen Label Regulation: In the U.S., dietary supplements dont require FDA pre-market approval
Myoglobin triggers ferroptosis in renal tubular epithelial cells, contributing to Crush Syndrome-associated acute kidney injury
Even when I weighed 380 pounds, I was a very active person." But the relationship between weight and health is far from simple